For example, in models of chronic lymphocytic leukemia (CLL), the Syk inhibitor fostamatinib (R788) reduced tumor cell survival and disrupted B cell receptor (BCR) signaling, which is crucial for leukemic cell maintenance (115, 116). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.